Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 3Breast Neoplasms 2

Interventions

Fulvestrant 82Paclitaxel 76Letrozole 76pembrolizumab 70Specimen Handling 63Trastuzumab 62Carboplatin 57Magnetic Resonance Spectroscopy 50ribociclib 49Capecitabine 48Anastrozole 47pertuzumab 46palbociclib 43exemestane 40abemaciclib 40Cyclophosphamide 40Tamoxifen 38Biopsy 36Docetaxel 30trastuzumab deruxtecan 28Taxes 27Radiotherapy 27Gemcitabine 25130-nm albumin-bound paclitaxel 25Blood Specimen Collection 24olaparib 22Surveys and Questionnaires 22Standard of Care 22sacituzumab govitecan 20eribulin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
famitinib × Breast × 90 days × Clear all
NCT05582499 2026-05-28

FASCINATE-N

Fudan University

Phase 2 Recruiting
716 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05749588 2026-04-16

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Fudan University

Phase 2 Recruiting
120 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06649331 2026-04-08

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Fudan University

Phase 2 Recruiting
160 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡